Citizens JMP Reiterates a Buy Rating on Sana Biotechnology (SANA) With a $5 PT

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the top strong buy stocks under $5 to buy now. In a report released on August 21, Reni Benjamin from Citizens JMP reiterated a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA), setting a price target of $5.00.

Sana Biotechnology, Inc. (NASDAQ:SANA) announced its fiscal Q2 2025 results on August 11, reporting a cash position of $72.7 million and a pro forma Q2 2025 cash position of $177.2 million. This includes gross proceeds from sales of common stock through the ATM and equity financing in July and August 2025.

The company also reported positive 6-month clinical results of the ongoing type 1 diabetes study, showing that “hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide.”

Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders.

While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.